Rosuvastatin plus ticagrelor decreases the risk of major adverse cardiovascular events and elevates cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention: A meta‑analysis

Several previous studies have reported that rosuvastatin plus ticagrelor is superior to ticagrelor monotherapy in patients receiving percutaneous coronary intervention (PCI); several others, however, dispute this. The present meta-analysis summarized relevant studies, aiming to comprehensively explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jinling, Jin, Xiaodong, Zhang, Limei, Shen, Hongshuai, Yu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587883/
https://www.ncbi.nlm.nih.gov/pubmed/37869634
http://dx.doi.org/10.3892/etm.2023.12224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587883/
https://www.ncbi.nlm.nih.gov/pubmed/37869634
http://dx.doi.org/10.3892/etm.2023.12224

Ejemplares similares